# ATP6V0D2

## Overview
ATP6V0D2 is a gene that encodes the ATPase H+ transporting V0 subunit d2, a critical component of the vacuolar ATPase (V-ATPase) complex. This protein is categorized as a transmembrane subunit and plays a pivotal role in the acidification of intracellular compartments, which is essential for various cellular processes, including protein degradation, receptor-mediated endocytosis, and neurotransmitter release. In osteoclasts, ATP6V0D2 is particularly important for bone resorption, as it facilitates the acidification necessary for the degradation of bone matrix. The gene's expression is upregulated during osteoclast differentiation, and its protein product is involved in the regulation of osteoclast maturation and function (Wu2009Atp6v0d2). Mutations or dysregulation of ATP6V0D2 have been implicated in bone disorders such as osteopetrosis and have potential associations with cancer susceptibility, highlighting its clinical significance (Tan2018Association; Wu2009Atp6v0d2).

## Function
The ATP6V0D2 gene encodes a subunit of the V-ATPase complex, specifically the d2 isoform, which is crucial for the function of osteoclasts in bone resorption. This protein is a component of the osteoclast-specific proton pump that mediates extracellular acidification, a key process in bone matrix degradation. The d2 subunit is predominantly expressed in osteoclasts and is highly induced by RANKL during osteoclast differentiation, with its expression significantly higher in mature osteoclasts compared to the d1 isoform (Wu2009Atp6v0d2).

ATP6V0D2 plays a dual role in osteoclasts: it regulates cell fusion during osteoclast maturation and is essential for the activity of extracellular acidification and bone resorption in mature osteoclasts. The protein interacts with other subunits of the V-ATPase complex, such as ATP6V0A3, suggesting its involvement in the efficient coupling of ATP hydrolysis and proton translocation (Wu2009Atp6v0d2). The absence of ATP6V0D2 leads to impaired bone resorption, as evidenced by reduced resorption pit formation and decreased acidification, highlighting its critical role in maintaining bone health (Wu2009Atp6v0d2).

## Clinical Significance
Mutations or alterations in the ATP6V0D2 gene can have significant clinical implications, particularly in bone-related conditions. ATP6V0D2 is a crucial component of the osteoclast-specific proton pump, which is essential for bone resorption through extracellular acidification. Disruption of ATP6V0D2 function can lead to osteopetrosis, a condition characterized by impaired bone resorption due to defective osteoclast activity (Wu2009Atp6v0d2). In mice, the knockout of ATP6V0D2 results in an osteopetrosis phenotype, although less severe than that observed in ATP6V0A3 knockout mice, indicating its critical role in osteoclast function (Wu2009Atp6v0d2).

Alterations in ATP6V0D2 expression have also been associated with cancer risk. Genetic variants in ATP6V0D2 have been linked to increased susceptibility to several cancers, including breast cancer, pancreatic cancer, and renal cell carcinoma. This association suggests that ATP6V0D2 may play a role in cancer development, possibly through its involvement in the autophagy lysosome pathway and intracellular acidification processes (Tan2018Association). While no direct mutations causing distal renal tubular acidosis (dRTA) have been identified in ATP6V0D2, its potential involvement in other conditions remains a subject of investigation (Smith2002Molecular).

## Interactions
ATP6V0D2, a subunit of the V-ATPase complex, is involved in several protein interactions crucial for its function in osteoclasts and other cellular processes. It physically interacts with the Atp6v0a3 subunit, another component of the V-ATPase complex, which is essential for bone resorption and extracellular acidification. This interaction has been demonstrated through co-immunoprecipitation and GST pull-down assays, indicating that ATP6V0D2 associates with the N-terminal domain of Atp6v0a3 (Wu2009Atp6v0d2).

ATP6V0D2 also interacts with Adrm1, a cell adhesion-promoting protein, identified through yeast two-hybrid screening and confirmed by co-immunoprecipitation in mammalian cells. This interaction suggests a role in osteoclast differentiation, as Adrm1 expression increases during osteoclast maturation (Kim2009Adrm1).

In macrophages, ATP6V0D2 is implicated in membrane fusion and lysosomal functions, potentially interacting with SNARE proteins, although specific interactions in this context are not detailed (Pessoa2019ATP6V0d2). These interactions highlight ATP6V0D2's role in various cellular processes, including bone resorption and immune responses.


## References


[1. (Smith2002Molecular) Annabel N. Smith, Katherine J. Borthwick, and Fiona E. Karet. Molecular cloning and characterization of novel tissue-specific isoforms of the human vacuolar h+-atpase c, g and d subunits, and their evaluation in autosomal recessive distal renal tubular acidosis. Gene, 297(1–2):169–177, September 2002. URL: http://dx.doi.org/10.1016/s0378-1119(02)00884-3, doi:10.1016/s0378-1119(02)00884-3. This article has 89 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0378-1119(02)00884-3)

[2. (Pessoa2019ATP6V0d2) Carina Carraro Pessoa, Luiza Campos Reis, Eduardo Milton Ramos-Sanchez, Cristina Mary Orikaza, Cristian Cortez, Erica Valadares de Castro Levatti, Ana Carolina Benites Badaró, Joyce Umbelino da Silva Yamamoto, Vânia D’Almeida, Hiro Goto, Renato Arruda Mortara, and Fernando Real. Atp6v0d2 controls leishmania parasitophorous vacuole biogenesis via cholesterol homeostasis. PLOS Pathogens, 15(6):e1007834, June 2019. URL: http://dx.doi.org/10.1371/journal.ppat.1007834, doi:10.1371/journal.ppat.1007834. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1007834)

[3. (Tan2018Association) Juan Tan, Linna Fu, Haoyan Chen, Jian Guan, Yingxuan Chen, and Jingyuan Fang. Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers. International Journal of Cancer, 143(1):80–87, February 2018. URL: http://dx.doi.org/10.1002/ijc.31288, doi:10.1002/ijc.31288. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.31288)

[4. (Kim2009Adrm1) Taesoo Kim, Hyun-Il Ha, Nacksung Kim, Okju Yi, Seoung Hoon Lee, and Yongwon Choi. Adrm1 interacts with atp6v0d2 and regulates osteoclast differentiation. Biochemical and Biophysical Research Communications, 390(3):585–590, December 2009. URL: http://dx.doi.org/10.1016/j.bbrc.2009.10.010, doi:10.1016/j.bbrc.2009.10.010. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2009.10.010)

[5. (Wu2009Atp6v0d2) Haiping Wu, Guoliang Xu, and Yi-Ping Li. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. Journal of Bone and Mineral Research, 24(5):871–885, May 2009. URL: http://dx.doi.org/10.1359/jbmr.081239, doi:10.1359/jbmr.081239. This article has 111 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1359/jbmr.081239)